PRLD
Prelude Therapeutics Inc
NASDAQ: PRLD · HEALTHCARE · BIOTECHNOLOGY
$5.23
+22.48% today
Updated 2026-04-30
Market cap
$275.98M
P/E ratio
—
P/S ratio
22.73x
EPS (TTM)
$-1.29
Dividend yield
—
52W range
$1 – $6
Volume
0.4M
Prelude Therapeutics Inc (PRLD) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+0.7%
Last 4 quarters
Revenue YoY growth
+41.0%
Most recent quarter
EPS YoY growth
+45.9%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+2.4%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+11.9%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-18 | $-0.20 | -53.8% | $3.43 | $3.19 | -7.0% |
| 2025-11-12 | $-0.26 | +29.7% | $1.35 | $1.51 | +11.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.13 | $-0.20 | -53.8% | $5.64M | +41.0% |
| 2025-09-30 | $-0.37 | $-0.26 | +29.7% | $6.50M | +116.7% |
| 2025-06-30 | $-0.48 | $-0.41 | +14.6% | — | — |
| 2025-03-31 | $-0.48 | $-0.42 | +12.5% | — | — |
| 2024-12-31 | $-0.47 | $-0.37 | +20.8% | $4.00M | +16.8% |
| 2024-09-30 | $-0.47 | $-0.43 | +8.5% | $3.00M | — |
| 2024-06-30 | $-0.43 | $-0.46 | -7.0% | — | — |
| 2024-03-31 | $-0.48 | $-0.42 | +12.5% | — | — |
| 2023-12-31 | $-0.49 | $-0.46 | +6.1% | $3.42M | — |
| 2023-09-30 | $-0.58 | $-0.45 | +22.4% | — | — |
| 2023-06-30 | $-0.63 | $-0.54 | +14.3% | — | — |
| 2023-03-31 | $-0.68 | $-0.58 | +14.7% | — | — |
| 2022-12-31 | $-0.63 | $-0.60 | +4.8% | — | — |
Frequently asked questions
Has Prelude Therapeutics Inc beaten earnings estimates?
Prelude Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +0.7% over the last 4 quarters.
How does PRLD stock react to earnings?
PRLD stock has moved an average of +2.4% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Prelude Therapeutics Inc's revenue growth rate?
Prelude Therapeutics Inc reported year-over-year revenue growth of +41.0% in its most recent quarter, with EPS growing +45.9% year-over-year.